Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginBlood Cancer Journal is a peer-reviewed fully open access journal dedicated to publishing articles related to hematologic malignancies and related disorders.
Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Blood Cancer Journal accepts the following article types. Click on an article type to view submission instructions.
Article
Review Article
Current Treatment Algorithm
Correspondence
Recent Publications
Infection burden among patients with triple-class–exposed RRMM receiving non–T-cell–redirecting therapies: a US claims study
Samer Al Hadidi, Eric Chinaeke, Jinghua He, Helen Pai, Agne Paner-Straseviciute, Ibrahim Saber, Jessica Fowler, Tonya Le Blanc, Niodita Gupta-Werner, Xinke Zhang, Shuchita Kaila
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification
Yi-Tsung Yang, Chi-Yuan Yao, Yong-Huai Yi, Chein-Jun Kao, Yuan-Yeh Kuo, Ming-En Lin, Hsin-An Hou, Chien-Chin Lin, Wen-Chien Chou, Hwei-Fang Tien
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Mansi R. Shah, Aishee Bag, Asis Shrestha, Yetunde Ogunsesan, Anup Trikannad, Sruthi Vellanki, Sanjay Muttineni, Hira Cheema, Syed Naqvi, Sasya Dronavalli, Samer Al Hadidi, Sharmilan Thanendrarjan, Maurizio Zangari, Frits van Rhee, Aniko Szabo, Rajshekar Chakraborty, Meera Mohan, Carolina Schinke
Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines
Meera Mohan, Anushareddy Muddasani, Hayder Alkhalisy, Lisa Rein, Jean Esselman, Binod Dhakal, Anita D’Souza, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Aniko Szabo, Carolina Schinke
Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Sarah Matarasso Greenfeld, Rakan Okde, Mark Sorin, Olivia Benguigui, Joseph Tuscano, Maria Sannikova, Eugene Nikitin, Lorenzo Falchi, Sarit Assouline
Frequently asked questions
How long does it take to publish?
Reviewers are given 14 days from acceptance to submit their reports. Revision requests are used when authors can address concerns in six months or less. Accepted articles are published immediately as an Article in Press. Proof corrections must be returned within 48 hours of receipt.
Reformat to Blood Cancer Journal using Livewrite PremiumIs a cover letter required?
A cover letter is required. It should include the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality and exclusive submission, include previous reviewer comments if the manuscript was considered elsewhere, and include a Competing Interests statement.
Reformat to Blood Cancer Journal using Livewrite PremiumWhat are the publication costs?
An article processing charge is required. Original Research: £3690.00/$5490.00/€4390.00; Letter / Correspondence / Comment: £1215.00/$1675.00/€1515.00, subject to VAT or local taxes where applicable.
Reformat to Blood Cancer Journal using Livewrite Premium